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Abstract
Background Muscle atrophy impacts almost every patient
seen for orthopaedic conditions. Unfortunately, no effec-
tive treatment is available to date. Matrix metallo-
proteinases (MMPs), especially MMP-2, are involved in
skeletal muscle atrophy. MMP-2 null mice reportedly have
substantially reduced muscle atrophy after tendon tran-
section compared with wild-type mice, suggesting MMP-2
plays an important role in muscle atrophy. Although the
exact mechanisms remain unknown, a newly-discovered
intracellular form of MMP-2 suggests a possible novel
mechanism of MMP-2 digesting muscle matrix during
muscle atrophy. I propose a new pharmacologic treatment
for muscle atrophy using selective MMP-2 inhibitors.
Questions/Hypothesis I hypothesize: (1) intracellular
MMP-2 plays an important role during muscle atrophy by
digesting intramuscular matrix; (2) AP-1 and NFAT signal
transduction pathways are responsible for expression and
activation of the intracellular MMP-2 during muscle atro-
phy; and (3) specific MMP-2 inhibitors can serve as a novel
pharmacologic strategy in treating disuse-induced muscle
atrophy.
Method of Study Expression and activity of extracellular
and intracellular MMP-2 will be determined in a mouse
tendon transection model. The role of AP-1 and NFAT
signal transduction pathways in MMP-2 transcriptional
regulation in muscle atrophy will be determined using
chromatin-immunoprecipitation (ChIP) and small interfer-
ing RNA (siRNA). I also will test the feasibility of treating
muscle atrophy using selective MMP-2 inhibitors.
Significance Understanding the signaling transduction
pathway of extracellular and intracellular MMP-2 expres-
sion during muscle atrophy may lead to novel treatments
for muscle atrophy that preserve the normal physiologic
function of MMP-2.
Hypothesis
I hypothesize: (1) intracellular MMP-2 plays an important
role during muscle atrophy by digesting intramuscular
matrix; (2) AP-1 and NFAT signal transduction pathways
are responsible for expression and activation of intracel-
lular MMP-2 during muscle atrophy; and (3) specific
MMP-2 inhibitors can serve as a novel pharmacologic
strategy in treating disuse-induced muscle atrophy.
Background
Atrophy is a harmful consequence of skeletal muscles
deprived of normal activity and often leads to major diffi-
culties with mobility and other activities of daily living
[2, 7, 10]. Decreased muscle protein synthesis and increased
muscle degradation are believed to be responsible for the
loss of muscle mass in muscle atrophy. Multiple prote-
ases, including the ubiquitin-proteasome system, lysosomal
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proteases, and calcium-dependent calpains, are involved in
skeletal muscle atrophy. Studies have indicated that MMPs
also are involved in this common muscle disorder. A recent
study suggests an intracellular MMP-2 form can digest
intracellular matrix under certain pathologic circumstances,
such as oxidative stress in the cardiac muscles [4]. I have
observed increased expression of MMP-2, MMP-9 [8], and
MMP-13 (unpublished data) during muscle atrophy after
tendon transection. However, substantially reduced muscle
atrophy was observed only in MMP-2 knockout mice, but
not in the MMP-9 knockout mice [5] and MMP-13
knockout mice (unpublished data). These findings sug-
gest MMP-2 plays a specific critical role during muscle
atrophy.
MMP-2 is tightly regulated at transcription, translation,
and posttranslation levels in myocytes. Tissue inhibitors of
metalloproteinases (TIMPs), especially TIMP-2, play an
important role in regulating the activity of MMP-2. TIMP-
2 plays a complicated role in regulating the activity of
MMP-2. It binds to MMP-2 and inactivates it. However, it
also facilitates binding of MMP-2 to MMP-14 (MMP-2
activator), thus activating MMP-2 [9]. An alternative
transcription of MMP-2 gene results in the pathologic
intracellular form of MMP-2 during oxidative injury in
cardiac muscles (Oral communication, David Lovett MD,
University of California – San Francisco. August 10,
2010). This intracellular MMP-2 remains in myocytes and
digests various intracellular substrates, including troponin I
in cardiac muscle [1].
Proposed Program
I will examine the expression and activity of extracellular
and intercellular MMP-2 in muscle atrophy. RT-PCR,
Western-blot, and zymography will be used to study the
expression of both MMP-2 isoforms in atrophic muscle.
Furthermore, immunohistochemistry and electron micros-
copy will be used, if necessary, to detect subcellular
distribution of intracellular MMP-2 in atrophic muscle
(Fig. 1).
First, two-dimensional electrophoresis and pull-down
assay will be used to identify intracellular and extracellular
substrates of MMP-2 during muscle atrophy. MMP-2
knockout mice will be used to study the functional role of
MMP-2 during muscle atrophy. In this study the role of
MMP-2 in the activation of the NFjB pathway in muscle
atrophy will be studied by comparing wild-type and
MMP-2 knockout mice.
The transcription regulation and corresponding signal
transduction pathways responsible for intracellular MMP-2
during muscle atrophy will be investigated. I will study the
role of AP-1 and NFAT signal transduction pathways in
MMP-2 transcriptional regulation in muscle atrophy using
chromatin-immunoprecipitation (ChIP) and small interfer-
ing RNA (siRNA).
I recently reported reduced muscle atrophy after
2 weeks of treatment with selective MMP-2 inhibitor [6].
No notable side effects were observed in the MMP-2
inhibitor-treated animals in this study. In the current pro-
posed study, the role of selective and nonselective MMP-2
inhibitors will be investigated in treating muscle atrophy in
a mouse tendon transection model.
Limitations
Inhibiting MMP-2 activity with a MMP-2 inhibitor may
cause undesired side effects by blocking normal physio-
logic functions of MMP-2, such as wound healing and
tissue remodeling in patients with muscle atrophy. How-
ever, this problem may be avoided by limiting application
of MMP-2 inhibitors in a relatively short period in patients
before physical rehabilitation or other measurements can
be applied (eg, during casting period). Furthermore,
observations from the proposed studies may help distin-
guish a signal transduction pathway that is responsible only
Fig. 1 A schematic shows extracellular and intracellular MMP-2 in
muscle atrophy. Normal transcription of MMP-2 generates extracel-
lular MMP-2 with a signal peptide, which directs it to the
extracellular matrix. An alternative transcription mechanism gener-
ates an intracellular form of MMP-2 without the signal peptide. The
intracellular MMP-2 remains inside the muscle cell and results in
intracellular matrix degradation of the muscle.
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for intracellular MMP-2 expression, thus helping to design
selective treatments that target this pathologic intracellular
MMP-2 isoform.
Next Steps
The next steps of this study will focus on examining the
role of MMP-2 inhibitors in treating muscle atrophy
through clinical trials. In bench studies, the feasibility of
treating muscle atrophy will be tested by blocking the
expression and activation of the pathologic intracellular
MMP-2.
Numerous synthesized MMP inhibitors have been in
clinical trials since the 1980s. To date, at least 58 clinical
trials for nine different MMP inhibitors have been con-
ducted. Many of these MMP inhibitors have in vivo
MMP-2 inhibitory activities [3]. Although various MMP
inhibitors have been tested for treatment of cancers and
other diseases, to date none has been tested for treatment of
skeletal muscle atrophy. A clinical trial testing the role of
MMP-2 inhibitor in treating muscle atrophy will be
initiated.
The molecular mechanisms of MMP-2 expression and
activation during muscle atrophy will be studied, and the
specific signal transduction pathways responsible for
extracellular and intracellular MMP-2s will be identified.
The feasibility of blocking intracellular MMP-2 expression
by blocking specific signal transduction pathways will be
tested.
Vision of the Future
In the next decade, I expect MMP-2 inhibitors will become
routine treatment for patients with muscle atrophy, at least
when physical rehabilitation or other measurements are not
applicable. Hopefully this research on the functional role of
MMP-2 in muscle atrophy will lead to more basic and
clinical research of this unique and interesting MMP family
member. MMP-2 has many functions beyond the extra-
cellular matrix which need to be revealed.
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